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ABSTRACT
Background
Data on birth outcome and offspring health after the appearance of breast cancer are
limited. The aim of this study was to assess the risk of adverse birth outcomes in women
previously treated for invasive breast cancer compared with the general population of mothers.
Methods and Findings
Of all 2,870,932 singleton births registered in the Swedish Medical Birth Registry during
1973–2002, 331 first births following breast cancer surgery—with a mean time to pregnancy of
37 mo (range 7–163)—were identified using linkage with the Swedish Cancer Registry.
Logistic regression analysis was used. The estimates were adjusted for maternal age, parity,
and year of delivery. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate
infant health and mortality, delivery complications, the risk of preterm birth, and the rates of
instrumental delivery and cesarean section.
The large majority of births from women previously treated for breast cancer had no adverse
events. However, births by women exposed to breast cancer were associated with an increased
risk of delivery complications (OR 1.5, 95% CI 1.2–1.9), cesarean section (OR 1.3, 95% CI 1.0–1.7),
very preterm birth (,32 wk) (OR 3.2, 95% CI 1.7–6.0), and low birth weight (,1500 g) (OR 2.9,
95% CI 1.4–5.8). A tendency towards an increased risk of malformations among the infants was
seen especially in the later time period (1988–2002) (OR 2.1, 95% CI 1.2–3.7).
Conclusions
It is reassuring that births overall were without adverse events, but our findings indicate that
pregnancies in previously treated breast cancer patients should possibly be regarded as higher
risk pregnancies, with consequences for their surveillance and management.
The Editors’ Summary of this article follows the references.
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The average age of women giving birth for the ﬁrst time has
gradually increased during the last decades in Sweden. At
present, the mean age at ﬁrst birth is 29 y. The incidence of
breast cancer is increasing in women of all ages.
Between 20% and 25% of breast cancer diagnoses are in
women under 50 y [1,2]. Some of these women face diagnosis
and treatment of breast cancer before they have started or
completed childbearing and need to be appropriately
counseled.
Knowledge about how breast cancer and its treatment
affect birth outcome and offspring health is limited. In a
recently published Danish cohort study [3] there was no
excess risk of adverse birth outcome for 216 newborns of
women with breast cancer before pregnancy compared with
women without breast cancer.
The aim of the present study was to assess delivery risks and
offspring health for births by previously treated breast cancer
patients compared with the general population. When the
study was initiated we hypothesized, based on the results of
two clinical reports [4,5] and our clinical experience, that no
difference would be detected.
Methods
The study is based on 2,870,932 singleton births, registered
in the Swedish Medical Birth Registry during 1973–2002.
Linking this register with the Swedish Cancer Registry, 414
births were identiﬁed of women with previously treated
invasive breast cancer. Invasive breast cancer was deﬁned
according to World Health Organization’s histological typing
of breast tumors. In total, 331 of the 414 births were the ﬁrst
births subsequent to breast cancer diagnosis, with a mean
time between breast cancer surgery and pregnancy of 37 mo
(range 7–163). Second and third births subsequent to breast
cancer diagnosis were excluded from the analysis in order to
analyze one birth linked to each woman exposed to breast
cancer who subsequently gave birth. In women without breast
cancer, all singleton births were included.
The Swedish Medical Birth Registry of the National Board
of Health Welfare has data from over 99% of all births in
Sweden since 1973 [6]. Starting with the ﬁrst antenatal visit,
antenatal, obstetric, and pediatric information are recorded
in a standardized manner.
Maternal age was deﬁned as age in completed years at the
time of delivery. Parity was deﬁned as number of previous
births, including stillbirths. Information about maternal
smoking was collected at the ﬁrst antenatal visit. Women
were classiﬁed in this study as nonsmokers or daily smokers
(one or more cigarettes per day). The woman’s country of
birth was also recorded, and whether the woman was living
with the child’s father.
During the period of 1973–2002, three different editions of
the International Classiﬁcation of Diseases were used (ICD-8:
1955–1986; ICD-9: 1987–1990; and ICD 10: 1991–2002).
The variable hypertension was deﬁned as essential hyper-
tension (diagnosed before pregnancy and registered as a
separate variable at the ﬁrst antenatal visit), gestational
hypertension, and/or preeclampsia/eclampsia using the fol-
lowing one or more diagnostic codes: ICD-8: 401 and 637;
ICD-9: 642; and ICD-10: O10–O16.
Diabetes was deﬁned as insulin-dependent diabetes present
before pregnancy, non-insulin-dependent diabetes present
before pregnancy, or gestational diabetes (ICD-8: 250; ICD-9:
250 and 648; and ICD-10: O24).
Complications during pregnancy and delivery were classi-
ﬁed by a physician when the woman was discharged. For an
outcome of pregnancy bleeding we used ICD-8: 632; ICD-9:
640–641; and ICD-10: O20 and O46; and for deliveries
complicated by placenta previa, ante- or postpartum hemor-
rhage, retained placenta, abnormal bone pelvis, fetopelvic
disproportion, malpresentation of fetus, prolonged labor,
rupture of uterus, laceration of perineum, or other compli-
cations we used ICD-8: 651–662; ICD-9: 652–669; and ICD10:
O45–O75. To register birth injury we used ICD-8: 772; ICD-9:
767; and ICD-10: P10–P15; and to register both major and
minor malformations we used ICD-8: 740–759; ICD-9: 740–
759; and ICD-10: Q0–Q99. All diagnostic codes were
registered as none or one or more.
Estimated gestational age was based on the ﬁrst day of the
last menstruation and/or on ultrasound examination per-
formed routinely at no later than 18 completed weeks of
gestation. During the two last decades, anomaly screening
ultrasound has been uniformly performed in Sweden.
The deﬁnition of a live birth was a newborn with a
gestational age of 22 wk or more that showed any evidence of
life, such as beating of the heart, pulsation of the umbilical
cord, or deﬁnite movement of voluntary muscles. Stillbirth
was deﬁned as late fetal death occurring at 28 or more
completed weeks of gestation. Preterm delivery was classiﬁed
as very preterm ( 32 wk) or preterm (33 to 36 wk).
Infants deﬁned as small for gestational age were those with
birth weights more than two standard deviations below the
mean birth weight for gestational age according to a Swedish
reference curve.
Apgar score at 5 min was categorized as (1) below seven or
(2) seven or greater because a previous population-based
study in Sweden showed that a 5-min Apgar score under
seven in term infants was associated with an increased risk of
neonatal morbidity and neurologic impairment [7].
The study was approved by the Ethical Committee for
Human Studies of Uppsala University.
The present study uses a cohort design and logistic
regression analysis to estimate odds ratios (ORs) for birth
outcome. The exposure of interest was breast cancer prior to
birth, and the events adverse birth outcomes as deﬁned
above. We considered age of mother, time period of delivery,
country of mother’s birth, history of infertility, family
situation, smoking habits, hypertension, and diabetes to be
possible confounders. After studying the distribution of these
variables among women exposed to breast cancer those not,
we kept age of mother, parity, and year of delivery as
variables of interest—both as possible confounders and
theoretically also as modiﬁers of the effect. We started the
analysis by stratifying on age of mother, parity, and year of
delivery, in periods of 5-y intervals. All crude estimates
regarding birth outcome and infant characteristics were
adjusted for age of mother (continuous), parity, and year of
delivery. When there was a binary response variable, the
logistic procedure with canonical (i.e., logit) link in SAS
version 8.2 (SAS Institute, http://www.sas.com) was used to
calculate the OR and its 95% conﬁdence interval (CI). When
there was a multinomial response variable, the generalized
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for multiple tests.
Results
The information on parity and maternal age was complete
for all individuals (Table 1). Women formerly exposed to
breast cancer (the BC group) were older at delivery, with a
mean age of 34 y, than the general population of mothers
(mean age 27 y), and more often had a history of infertility
lasting more than 1 y (OR 2.53, 95% CI 1.6–3.9). Parity and
frequencies of hypertensive disease, smoking, living with the
father, and diabetes were comparable between the BC group
and women not exposed to breast cancer.
The OR for delivery complications was increased among
women in the BC group (Table 2). Delivery complications
were registered as none or one or more. Thirty-one percent
of infants of women in the BC group were delivered by
instrument or by cesarean section, compared to 17% in
women not exposed to breast cancer.
The characteristics of the infants born to the 331 women in
the BC group compared with women without breast cancer
are shown in Table 3. Eleven percent of the infants of women
in the BC group were delivered preterm (before week 37),
compared with 5% of infants born to women without a
previous breast cancer.
We found no increased risk of reduced birth weight for
gestational age in infants of mothers in the BC group: the OR
for infants being small for their gestational age was 1.2 (95%
CI 0.90–1.39) compared to the general population of infants.
The OR for delivering an infant with an Apgar score below
seven at 5 min was not increased among women in the BC
group.
Malformation, major or minor, was registered in 7.5% of
the infants of women in the BC group compared to 4.3%
among mothers without a previous breast cancer (Table 3). A
tendency towards an increased risk of malformations in the
infants of mothers who have had breast cancer was seen
especially in the later time period of births (1988–2002)—OR
2.1 (95% CI 1.2–3.7)—in contrast to the ﬁrst time period
(1973–1987), with an OR of 1.3 (95% CI 0.7–2.5).
In infants of women in the BC group, nine malformations
were registered between 1973 and 1987 and 15 between 1988
and 2002. The diagnoses in these 24 offspring were as follows:
ten cardiac defects (including three children with patent
ductus arteriosus and four with septal defects), three kidney/
ureteragenesis defects, two undescended testes in full-term
infants, two unspeciﬁed limb malformations, two ear malfor-
mations, two skin malformations, one chromosome anomaly
(trisomy 21), one congenital hydrocephaly, and one orofacial
cleft. Only one malformation diagnosis for each infant was
found.
Discussion
In the present study, with 331 births subsequent to breast
cancer, the large majority of infants were born alive, full
term, with Apgar scores at 5 min of seven or more, and with
no malformation. Regarding stillbirth and infant death—
arguably the most serious adverse outcomes—the result of the
current study is reassuring. Only four deaths in 331 births of
mothers in the BC group were identiﬁed. Still, we found a
Table 1. Characteristics of Women Delivering the First Infant Subsequent to Breast Cancer Compared with the General Population of
Women Delivering Infants
Characteristic Subcategory Mothers Exposed to Breast Cancer
(n ¼ 331), Number (Percent)
Mothers Not Exposed to Breast Cancer
(n ¼ 2,870,518), Number (Percent)
Age (years)
a  19 1 (1%) 107,766 (4%)
20–29 51 (15%) 1,731,074 (60%)
30–34 104 (31%) 718,985 (25%)
 35 175 (53%) 311,700 (11%)
Time period of delivery 1973–1987 151 (46%) 1,449,011 (50%)
1988–2002 180 (54%) 1,421,422 (50%)
Parity 1 192 (58%) 1,501,437 (52%)
2 78 (24%) 940,859 (33%)
3þ 61 (18%) 428,222 (15%)
Country of birth Missing 41 (12%) 546,173 (19%)
Non-Nordic 19 (6%) 203,241 (7%)
Nordic 271 (82%) 2,121,104 (74%)
History of infertility No 309 (93%) 2,791,991 (97%)
.1 y 22 (7%) 78,527 (3%)
Family situation Missing 110 (33%) 1,048,716 (37%)
Single 12 (4%) 98,479 (3%)
Living with the child’s father 209 (63%) 1,723,323 (60%)
Smoking habits Missing 103 (31%) 1,047,102 (37%)
Nonsmoker 183 (55%) 1,419,133 (49%)
Smoker 45 (14%) 404,283 (14%)
Hypertension No 324 (98%) 2,787,685 (97%)
Yes 7 (2%) 82,833 (3%)
Diabetes No 330 (.99%) 2,858,719 (.99%)
Yes 1 (,1%) 11,799 (,1%)
aThe mean age for women exposed to breast cancer was 34 y and for women not exposed to breast cancer was 27 y.
DOI: 10.1371/journal.pmed.0030336.t001
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an increased risk for delivery complications, cesarean section,
preterm birth, and low birth weight. These associations
remained almost unchanged after adjustment for possible
maternal confounders such as age and parity.
The strengths of the study are that it is population-based,
covers a large number of pregnancies over a long time period,
and has no losses to follow-up, and that the registries have
near complete information on all key variables. The Swedish
Cancer Registry has over 95% sensitivity in registration of all
breast cancers in the country.
A drawback of the study approach is that we have no
information for individuals on the type of treatment for
breast cancer they received, or on the timing and course of
the disease with respect to the pregnancy. Thus, we cannot
deﬁne subgroups with higher or lower risks within those
exposed to breast cancer. We also had no data on and
therefore could not control for maternal use of antidepres-
sants, reported to be associated with preterm birth [9]. There
is no information available on whether pregnant women with
a previous breast cancer use antidepressants more often than
other pregnant women. Another limitation of the study is the
possibility of misclassiﬁcation of the outcome variables:
during the study period three different ICD classiﬁcations
of diagnoses were used, which could lead to registration
artifacts.
There have been studies of the accuracy of the data on
pregnancy and malformations in the Swedish Medical Birth
Registry [10–12]. A questionnaire on pregnancy outcome was
distributed to 782 women in Sweden [10]. Only 50% of self-
reported less severe malformations were found in the central
registry, but the agreement between the questionnaire data
and the registry was good for serious malformations.
Regarding birth weight, there was agreement in 72% of cases.
Table 2. Crude and Adjusted ORs for Birth Outcome in Women Previously Treated for Breast Cancer Compared with the General
Population
Characteristic Subcategory Women Exposed to Breast Cancer
(n ¼ 331), Number (Percent)
Women Not Exposed to Breast Cancer
(n ¼ 2,870 518), Number (Percent)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
a
Pregnancy bleeding No 327 (99%) 2,845,484 (99%) 1 1
Yes 4 (1%) 2,503 (1%) 1.39 (0.52, 3.73) 1.32 (0.49, 3.56)
Delivery complication No 160 (48%) 1,861,216 (65%) 1 1
One or more 171 (52%) 1,009,302 (35%) 1.97 (1.59, 2.45) 1.50 (1.20, 1.90)
Instrumental delivery No 298 (90%) 2,690,147 (94%) 1 1
Yes 33 (10%) 180,341 (6%) 1.65 (1.15, 2.37) 1.43 (0.99, 2.06)
Cesarean section No 261 (79%) 2,560,069 (89%) 1 1
Yes 70 (21%) 310,419 (11%) 2.21 (1.70, 2.88) 1.26 (1.00, 1.66)
aAdjusted for continuous age, year of delivery, and parity.
DOI: 10.1371/journal.pmed.0030336.t002
Table 3. Characteristics of Infants Born to Women Previously Treated for Breast Cancer Compared with the General Population of
Infants Born
Characteristic Subcategory Mother Exposed to Breast Cancer
(n ¼ 331), Number (Percent)
Mother Not Exposed to Breast Cancer
(n ¼ 2,870,518), Number (Percent)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
a
Gestational age ,32 wk 10 (3%) 20,265 (1%) 4.52 (2.41, 8.49) 3.20 (1.70, 6.03)
32–36 26 (8%) 128,560 (4%) 1.85 (1.24, 2.77) 1.53 (1.02, 2.29)
37–42 292 (88%) 2,674,685 (93%) 1 1
42þ 3 (1%) 38,811 (2%) 0.71 (0.23, 2.21) 0.87 (0.28, 2.71)
Mortality Live born, alive   7 d 327 (99%) 2,851,969 (99%) 1 1
Stillbirth 2 10,307 1.69 (0.42, 6.80) 1.17 (0.30, 4.71)
Live born, alive , 7 d 2 8,242 2.12 (0.53, 8.50) 1.83 (0.46, 7.37)
Birth weight Missing 2 (1%) 8,701 (,1%)
,1,500 g 8 (2%) 17,484 (1%) 4.12 (2.04, 8.31) 2.86 (1.41, 5.78)
1,500–2,499 12 (4%) 85,980 (3%) 1.26 (0.70, 2.24) 0.98 (0.55, 1.75)
2,500–4,499 296 (89%) 2,662,632 (93%) 1
4,500þ 13 (4%) 95,721 (3%) 1.22 (0.70, 2.13) 1.10 (0.63, 1.92)
Apgar score Missing 18 (5%) 238,276 (8%)
0–6 7 (2%) 34,493 (1%) 1.72 (0.81, 3.64) 1.41 (0.69, 3.10)
7–10 306 (93%) 2,597,749 (91%) 1 1
Birth trauma No 325 (98%) 2,778,735 (97%) 1 1
Yes 6 (2%) 91,783 (3%) 0.56 (0.25, 1.25) 0.58 (0.26, 1.30)
Malformation No 307 (93%) 2,748,213 (96%) 1 1
Yes 24 (7%) 122,305 (4%) 1.76 (1.16, 2.66) 1.68 (1.11, 2.54)
aAdjusted for continuous age, year of delivery, and parity.
DOI: 10.1371/journal.pmed.0030336.t003
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cations are non-differential with regard to a previous breast
cancer diagnosis on the part of the mother, which, if
anything, will lead to an underestimation of the ORs rather
than spurious positive ﬁndings. The increased use of cesarean
section in women with breast cancer may, however, very well
be a consequence of increased fetal monitoring.
As this is a birth registry study, major malformations that
led to pregnancy termination would not be counted in either
group. However, it is unlikely that the difference in severe
malformations reported here is a consequence of surveillance
or diagnostic bias in this study, since a serious malformation
would be regarded as a major medical event in all women and
not easily overlooked.
Healthy offspring have been reported delivered from small
series of breast cancer patients [4,5], and a recent large
Danish cohort study [3] also has shown reassuring results. No
increased risk of preterm birth, low birth weight, stillbirth, or
congenital abnormalities was seen in 216 infants born in
1943–2002 of women with breast cancer before pregnancy.
There may be several reasons why the results differ between
the Danish and the present Swedish cohort. There may be
different degrees and patterns of misclassiﬁcation of the
outcome variables between the registries. There may be
differences in the usage of adjuvant radiotherapy or systemic
treatments after breast cancer. The time trend in risk for
malformations seen in our study supports the notion that
chemotherapy may be a driving force behind the risks, as use
of chemotherapy in younger patients has increased sharply
since 1988.
As the incidence of breast cancer in women less than 50 y
of age is increasing, data about the impact of adjuvant
therapy on reproductive potential and offspring outcome are
needed. Cytotoxic agents are preferentially toxic to rapidly
dividing cells and demonstrate teratogenic effects that can
cause malformations when administered in the ﬁrst trimester
of pregnancy [13]. During the second and third trimester,
fetal growth and functional development, especially that of
the brain, may be affected [13]. No increase in birth defects
has been demonstrated in children whose parents were
exposed to chemotherapy earlier in life [5,14–16].
Little is known about the late effects of chemotherapy on
offspring. Mulvihill et al. [17] reported on 58 pregnancies
occurring with a mean time of 27 mo after chemotherapy for
various malignancies. During the ﬁrst year after chemo-
therapy, an increase in low birth weight—mainly due to
premature birth—stillbirth, and premature termination of
pregnancy was seen, but no excess of congenital anomalies.
Having a malignancy and subsequent pregnancy raises
questions about the mother and her disease, on the one hand,
and the management of the fetus, on the other. Breast cancer
survivors who want to become pregnant need information
about potential risks. Breast cancer patients’ prognosis does
not seem to be worsened by pregnancy [18–20]. The knowl-
edge of potential risks for delivery offspring health compared
to that of the general population has so far been scanty.
Furthermore, there are few studies in which the character-
istics of pregnant breast cancer patients are compared with
those of the general population.
We hypothesized wrongly that no increased risk of adverse
birth outcomes would be detected. While it should be pointed
out that the large majority of births had no complications,
one may consider that based on our observations, pregnan-
cies in previously treated breast cancer patients should be
regarded as higher risk pregnancies, with consequences for
their surveillance and management.
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Breast Cancer and Birth OutcomeEditors’ Summary
Background. More women of all ages are developing breast cancer than
ever before. In the US, one woman in eight will now develop this disease
during her lifetime. For most of these women, their breast cancer
diagnosis will come late in life, but a fifth of breast cancers are diagnosed
before the age of 50. These days, the long-term outlook for women with
breast cancer is quite good; 80% of women who receive a diagnosis of
breast cancer survive more than five years. These figures, together with a
trend towards starting families later in life—since the late 1970s birth
rates for women in their late 30s and 40s have more than doubled in the
US, and in Sweden the average age for having a first baby is now 29
years—mean that many women who have had breast cancer want to
have children. One estimate is that up to 7% of women who are fertile
after treatment for breast cancer will later have children.
Why Was This Study Done? Pregnancy seems to have no adverse
affects on women who have had breast cancer—there is no evidence
that pregnancy can trigger a relapse. However, little is known about
whether the chemotherapy and radiotherapy used to treat breast cancer
have any long-lasting effects that might result in a poor birth outcome
such as stillbirth, low birth weight, premature delivery, or abnormalities
in the baby (congenital abnormalities). In this study, the researchers
assessed the risk of adverse birth outcomes in women previously treated
for breast cancer in Sweden.
What Did the Researchers Do and Find? Nearly three million singleton
births that occurred between 1973 and 2002 are recorded in the Swedish
Medical Birth Registry. The researchers linked this information with that
in the Swedish Cancer Registry to identify 331 first births after treatment
for invasive breast cancer (cancer that has spread from where it started
to grow in the breast). The birth registry includes details on maternal age
and health, child’s birth weight, whether the delivery was preterm, and
whether the child had any congenital abnormalities, so the researchers
were able to compare birth outcomes in these 331 births with those in
the general population. They discovered that most births after breast
cancer treatment went smoothly. There was no increase in stillbirths, but
there were slightly more delivery complications in the women who had
had breast cancer than in the general population, and a slight increase in
babies born prematurely or with low birth weight. Finally, a few more
babies with congenital abnormalities were born to women after breast
cancer treatment than to women in the general population.
What Do These Findings Mean? Overall, these results should reassure
women who are thinking about having children after breast cancer
about the health of their future offspring. However, they do suggest that
these women may need careful monitoring during late pregnancy and
delivery. This result was not predicted by the researchers who performed
the study. Before starting the study, they thought that there would be no
difference in birth outcomes between patients previously treated for
breast cancer and the general population. Furthermore, a recently
published similar study in Denmark found no increased risk of preterm
birth, low birth weight, or congenital abnormalities after breast cancer.
Differences between the two countries in the accuracy of their registries
or in the use of chemotherapy and radiotherapy treatments may account
for this difference in results. Additional studies are now needed in other
populations to resolve this discrepancy and to provide more information
about how breast cancer treatment might affect birth outcomes. For
example, the current study did not provide any information about
whether specific chemotherapy regimens or different types of breast
cancer might put women at a higher risk of adverse birth outcomes, or
whether the time between the cancer diagnosis and treatment and the
pregnancy made a difference.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030336.
  MedlinePlus encyclopedia entry on breast cancer
  National Cancer Institute information for patients and physicians on
breast cancer, including links to pages on breast cancer and
pregnancy
  Cancer Research UK’s information on breast cancer for patients, and
statistics on breast cancer in the UK
  Wikipedia page on breast cancer (note: Wikipedia is a free online
encyclopedia that anyone can edit)
  Royal College of Obstetricians and Gynaecologists guidelines for
physicians on pregnancy and breast cancer
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